Bottom line
XLV vs IHE: the short answer
XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) and IHE (iShares U.S. Pharmaceuticals ETF) share a meaningful slice of their top holdings — about 42% by weight.
XLV is cheaper at 0.08% vs 0.37% — a difference of $29 a year per $10,000 invested.
Over five years, IHE returned +9.1% a year vs +8.1% for XLV.
Updated Nov 19, 2026
XLV vs IHE side by side
| XLV | IHE | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | SPDR (State Street) | iShares |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.08% | 0.37% |
| Annual cost per $10k | $8 | $37 |
| 10-yr cost on $10k (prospectus) | $103 | $468 |
| Max front load | None | None |
| 12b-1 fee | 0.02% | 0% |
| 1-yr return | +14.5% | +31.7% |
| 5-yr return (annualized) | +8.1% | +9.1% |
| 10-yr return (annualized) | +9.8% | +6.2% |
| Best quarter | +14.5% | +17.6% |
| Worst quarter | −12.7% | −16.0% |
| Net assets (fund) | $40.6B | $1.1B |
| Number of holdings | 65 | 59 |
| Portfolio turnover | 2% | 29% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | XLV | IHE | Difference |
|---|---|---|---|
| 2025 | +14.5% | +31.7% | −17.2% |
| 2024 | +2.5% | +8.1% | −5.6% |
| 2023 | +2.0% | +1.0% | +1.0% |
| 2022 | −2.1% | −4.8% | +2.7% |
| 2021 | +25.9% | +12.8% | +13.1% |
| 2020 | +13.3% | +13.8% | −0.5% |
| 2019 | +20.7% | +15.5% | +5.2% |
| 2018 | +6.3% | −7.7% | +14.0% |
| 2017 | +21.7% | +10.7% | +11.0% |
| 2016 | −2.8% | −11.7% | +8.9% |
Source: Fund prospectus bar charts
Holdings overlap
5 of XLV's top 25 holdings also appear in IHE's top 25.
| Holding | XLV | IHE |
|---|---|---|
| Eli Lilly & Co | 16.51% | 22.25% |
| Johnson & Johnson | 10.64% | 22.44% |
| Merck & Co Inc | 5.52% | 4.55% |
| Pfizer Inc | 2.39% | 3.96% |
| Bristol-Myers Squibb Co | 2.05% | 4.37% |
Source: SEC Form N-PORT
XLV top 10
- Eli Lilly & Co — 16.51%
- Johnson & Johnson — 10.64%
- AbbVie Inc — 7.74%
- UnitedHealth Group Inc — 6.57%
- Merck & Co Inc — 5.52%
- Amgen Inc — 3.40%
- Thermo Fisher Scientific Inc — 3.24%
- Abbott Laboratories — 2.75%
- Gilead Sciences Inc — 2.73%
- Intuitive Surgical Inc — 2.45%
IHE top 10
- Johnson & Johnson — 22.44%
- Eli Lilly And Company — 22.25%
- BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares — 6.24%
- Merck & Co., Inc. — 4.55%
- Bristol-myers Squibb Company — 4.37%
- Royalty Pharma Plc — 4.34%
- Viatris Inc. — 4.22%
- Pfizer Inc. — 3.96%
- Zoetis Inc. — 3.73%
- Jazz Pharmaceuticals Public Limited Company — 3.45%
FAQ
What is the difference between XLV and IHE?
Which is cheaper, XLV or IHE?
Should I own both XLV and IHE?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.